More than 150 biotech executives and investors took a stand against President Donald Trump's immigration ban, saying the controversial executive order threatens to undermine a multibillion-dollar industry that relies on a diverse workforce.
Trump's order — currently suspended while a federal appeals court weighs its merits — barred nationals from seven Muslim-majority nations from entering the US, regardless of their legal status. For biotech, an industry that relies heavily on foreign-born workers, the ban is particularly ominous, executives wrote in a letter to Nature Biotechnology.
